TIMI 15B

TIMI 15B evaluated the pharmacodynamic response, safety and pharmacokinetics of the GP IIb/IIIa inhibitor RPR 109891 given intravenously followed by oral administration for the treatment of patients with acute coronary syndromes.

PRESENTATIONS

TIMI 15B Slides

PUBLICATIONS

First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close